Immunological Evaluation of Recent MUC1 Glycopeptide Cancer Vaccines
Open accessThe DOI matches its Crossref record; 85 of the 88 references it cites were found in a registry or an index.
Abstract
Aberrantly glycosylated mucin 1 (MUC1) is a recognized tumor-specific antigen on epithelial cell tumors. A wide variety of MUC1 glycopeptide anti-cancer vaccines have been formulated by many research groups. Some researchers have used MUC1 alone as an immunogen whereas other groups used different antigenic carrier proteins such as bovine serum albumin or keyhole limpet hemocyanin for conjugation with MUC1 glycopeptide. A variety of adjuvants have been used with MUC1 glycopeptides to improve their immunogenicity. Fully synthetic multicomponent vaccines have been synthesized by incorporating different T helper cell epitopes and Toll-like receptor agonists. Some vaccine formulations utilized liposomes or nanoparticles as vaccine delivery systems. In this review, we discuss the immunological evaluation of different conjugate or synthetic MUC1 glycopeptide vaccines in different tumor or mouse models that have been published since 2012.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takeuchi, O., Hoshino, K., Kawai, T., Sanjo, H., Takada, H., Ogawa, T., Takeda, K., & Akira, S. (1999) · Immunity · doi:10.1016/s1074-7613(00)80119-3 · Cited by 3,362
Sakaguchi, S. (2005) · Nature Immunology · doi:10.1038/ni1178 · Cited by 2,669
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
Cheever, M. A., Allison, J. P., Ferris, A. S., Finn, O. J., Hastings, B. M., Hecht, T. T., Mellman, I., Prindiville, S. A., Viner, J. L., Weiner, L. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0737 · Cited by 1,388 · cited 1×
“That is why the National Cancer Institute has placed MUC1 as a second prioritized cancer antigen for translational research [1].”
BackgroundToll-like receptors and cancer
Rakoff-Nahoum, S., & Medzhitov, R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2541 · Cited by 925 · cited 8×
“The γ-PGA was included to stimulate APCs to produce cytokines.”
BackgroundInfluentialT Cell-Independent Antigens Type 2
Mond, J. J. (1995) · Annual Review of Immunology · doi:10.1146/annurev.immunol.13.1.655 · Cited by 824 · cited 5×
“Surprisingly they often found stronger immune responses to vaccines in buffer solution compared to vaccines in Freund’s adjuvant, particularly with regard to tumor binding antibodies and activation of complement dependent cytotoxicity (CDC).”
BackgroundInfluentialGhiringhelli, F., Puig, P. E., Roux, S., Parcellier, A., Schmitt, E., Solary, E., Kroemer, G., Martin, F., Chauffert, B., & Zitvogel, L. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050463 · Cited by 776
Ju, T., & Cummings, R. D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.262438199 · Cited by 487 · cited 3×
“Tumors are deficient in core 1,3-galactosyl-transferase (T synthase) which causes the MUC1 to be aberrantly glycosylated and produce carbohydrate structures such as Tn (GalNAcα-Ser or -Thr), STn (Neu5Ac-α (2,6)-GalNAcα-Thr) and TF antigen (Gal-β (1,3)-GalNAcα-Thr) [3].”
BackgroundInfluentialBarnd, D. L., Lan, M. S., Metzgar, R. S., & Finn, O. J. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.18.7159 · Cited by 449 · cited 2×
“In order to generate an effective anti-cancer vaccine response, the vaccine candidate should produce both humoral and cellular immunity [22].”
BackgroundRegulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy
Colombo, M. P., & Piconese, S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2250 · Cited by 407
Cited by
MUC1: Structure, Function, and Clinic Application in Epithelial Cancers
Chen, W., Zhang, Z., Zhang, S., Zhu, P., Ko, J. K.-S., & Yung, K. K.-L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126567 · Cited by 246
A review on development of MUC1-based cancer vaccine
Gao, T., Cen, Q., & Lei, H. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110888 · Cited by 151
Phage display as a tool for vaccine and immunotherapy development
Hess, K. L., & Jewell, C. M. (2020) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10142 · Cited by 134
“MUC1 is expressed by many types of cancer cells and is therefore an interesting target for cancer immunotherapies.(101,102) By incubating phages expressing the various epitopes with sera from immunized mice, a region of interest (SAPDTRPAP) was discovered.”
BackgroundDevelopments in Carbohydrate-Based Cancer Therapeutics
Hossain, F., & Andreana, P. R. (2019) · Pharmaceuticals · doi:10.3390/ph12020084 · Cited by 134
Koltai, T., Reshkin, S. J., Carvalho, T. M. A., Molfetta, D. D., Greco, M. R., Alfarouk, K. O., & Cardone, R. A. (2022) · Cancers · doi:10.3390/cancers14102486 · Cited by 130
Metadata
- Authors
- Hossain, M., & Wall, K.
- Affiliations
- University of Toledo (US)
- Corresponding author
- Wall, Katherine
- Venue
- Vaccines
- Publisher
- MDPI AG
- Published
- 2016-07-26
- Volume
- 4
- Issue
- 3
- Pages
- 25
- ISSN
- 2076-393X (ISSN-L)
- PMC
- PMC5041019
- OpenAlex
- W2480252091
- Cited by
- 74
- References
- 88
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 6 · 2023: 6 · 2022: 9 · 2021: 8 · 2020: 12 · 2019: 8 · 2018: 11 · 2017: 7
- FWCI
- 0.84
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Vaccines (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (GM094734)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Keywords
- MUC1 glycopeptide, cancer vaccines, tumor-specific antigens, mucin glycosylation, antigen conjugation, bovine serum albumin, keyhole limpet hemocyanin, vaccine adjuvants, helper T cell epitopes, TLR agonists, liposomes, nanoparticles, vaccine delivery systems, immunogenicity, tumor models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunological Evaluation of Recent MUC1 Glycopeptide Cancer Vaccines. https://app.cochat.ai/papers/10.3390/vaccines4030025
- The paper
- Hossain, M., & Wall, K. (2016). Immunological Evaluation of Recent MUC1 Glycopeptide Cancer Vaccines. Vaccines. https://doi.org/10.3390/vaccines4030025
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.